Will HIV Win and Lung Cancer Loss in Trials Recast Merck's (MRK) Risk Reward Narrative?
|
In early June 2026, Gilead Sciences and Merck reported
that their investigational once-weekly oral HIV regimen of
islatravir/lenacapavir met the ... |
Misinformation threatens rollout of HIV prevention drug lenacapavir
Health experts say false claims about the lenacapavir injection could undermine efforts to reduce new HIV infections in South Africa. View article...